Mid-term report 2013 - The European LeukemiaNet

European LeukemiaNet Midterm Report, 08-RNP-071
3. European added value and ELN visibility
The ELN will continue to set high standards for the investigation of all leukemias in Europe
and qualify medical doctors and scientists with educational activities on treatment
recommendations, new insights in the emergence of the disease and innovative research.
The ELN brings together in a collaborative action across Europe
113 leading national leukemia study groups (Fig. 1)
109 interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines)
(more than 1000 physicians and scientists
193 centers in 39 countries
Major achievements include:
• Cooperation to overcome fragmentation within the European leukemia research area
• International cooperation with centers and scientists in US, Japan and Australia.
• Accomplishment of a unique leukemia specific infrastructure given by the three
network centers responsible for management (NMC), information (ELIC) and
statistics/biometry (CICS) (WP1-3,17).
• Clinical trials on a European scale through collaboration of the leading national
leukemia trial groups on the different leukemia entities (WP4-9) and the
interdisciplinary partner groups in diagnostics and therapy research (WP10-15)
• Standardized protocols for clinical trials with uniform diagnostic procedures to achieve
comparable data, resulting in better and equal treatment options across national
borders
• Networks of reference laboratories in leukemia diagnostics and pharmacogenetics
across Europe (WP12, EUTOS for CML)
• Management recommendations for all leukemias
• Registries for information on current treatment and best treatment options (EUTOS
for CML, EU-MDS, APL, CLL, MPN)
• Improvement of patient care due to personalized treatment options
• Spread of excellence (ELN Website and publications) and high level training and
education to all physicians and researchers within leukemia research.
The ELN is committed to sustain the collaborations within and outside the network and to
further develop high quality standards in leukemia research, diagnosis and treatment.
Global collaboration will strengthen the ELN Network within and outside Europe.
The ELN is already collaborating with networks outside ESF countries. International
collaborations are currently ongoing in the US, Uruguay, Australia, Canada, Israel, Japan,
Korea and Russia.
14